Healthcare Professional Manufacturing Presentation Provider 
Physician's Weekly
JUNE 18, 2025
Cost-sharing interventions and patient education can help improve access to GLP-1 receptor agonists for patients with obesity, according to an abstract presented at the AACE Annual Meeting 2025. Other Persistent Barriers & Potential Solutions In another article not presented at the meeting, Stephanie W.
GeriPal
JUNE 20, 2024
Accreditation In support of improving patient care, UCSF Office of CME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
GeriPal
MAY 8, 2025
Alex 00:59 And I met all three of you and watched you do a presentation about psilocybin research at the Congress International Desens Palliative Miguel. Alex 06:03 Is psilocybin that’s used for medicinal purposes in your studies, for example, is that manufactured or is it derived directly from mushrooms? So when we did have.
FDA Law Blog
AUGUST 21, 2023
Recall that the funds provided under the Prescription Drug User Fee Acts (PDUFA) are not available to support the agency’s efforts related to monograph drugs.) This is because the presumption that manufacturers can unilaterally make substantive changes to the labeling of an OTC Monograph drug product is false.
GeriPal
MARCH 24, 2022
And I would say too, as a primary care provider, it really doesn’t take that long to ask people about a surrogate decision maker. The challenge is not that people made decisions differently, and it was difficult, the challenge was the healthcare professionals who said, “This is not working for me. I need structure.”
FDA Law Blog
MAY 21, 2024
The Attorney General also released DOJ’s Office of Legal Counsel (“OLC”) opinions providing the rationale and support for the NPRM. The Attorney General, after considering HHS’ recommendations, “concludes that there is, at present, substantial evidence that marijuana does not warrant control under schedule I.” 44,597 (May 21, 2024).
FDA Law Blog
JUNE 1, 2025
Commissioner Makary has taken a more subdued stance, stating in a podcast with Megyn Kelly that FDA doesnt have any plans to ban direct-to-consumer advertising, but there are some things that we can do to make sure that the information being presented is a complete picture.
Expert insights. Personalized for you.
52 
Let's personalize your content